Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Alert Lower Celexa dose in those over 60 QT prolon

Posted by Phillipa on March 29, 2012, at 19:35:08

Seems like now the SSRI's are being found to cause all sorts of problems. Newest alert is that celexa at doses over 20mg can cause QT prolongation of heart. Others conditions also. Phillipa


From News Alerts > Medscape Medical News

Lower Citalopram Dose Needed in Older Patients, FDA Warns

Caroline Cassels


March 28, 2012 The selective serotonin reuptake inhibitor (SSRI) citalopram (Celexa, Forest Laboratories) should not be used at doses greater than 20 mg per day in adults older than 60 years because of a potential risk for QT prolongation, the FDA warns.

Citalopram use at any dose is discouraged in patients with certain conditions because of the risk of QT prolongation, but because it may be important for some of those patients to use citalopram, the drug label has been changed to describe the particular caution that needs to be taken when citalopram is used in such patients.

The revised drug label also describes lower doses that should be used in patients older than 60 years.

Citalopram (Celexa).

Specifically the FDA states:

Citalopram is not recommended for use at doses greater than 40 mg per day because such doses cause too large an effect on the QT interval and confer no additional benefit.

Citalopram is not recommended for use in patients with congenital long QT syndrome, bradycardia, hypokalemia, or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.

Citalopram use is also not recommended in patients who are taking other drugs that prolong the QT interval.

The maximum recommended dose of citalopram is 20 mg per day for patients with hepatic impairment, patients who are older than 60 years, patients who are CYP2C19 poor metabolizers, or patients who are taking concomitant cimetidine (Tagamet, GlaxoSmithKline) or another CYP2C19 inhibitor, because these factors lead to increased blood levels of citalopram, increasing the risk for QT interval prolongation and torsade de pointes.

More information on today's warning is available on the FDA Web site.

Adverse events related to citalopram should be communicated to MedWatch by telephone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at the Medwatch Web site, or by mail to 5600 Fishers Lane, Rockville, Maryland 20852-9787.

 

Thread

 

Post a new follow-up

Your message only Include above post


[1014471]

Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Phillipa thread:1014471
URL: http://www.dr-bob.org/babble/20120328/msgs/1014471.html